JP2022505923A - 抗tim-3抗体を投与する方法 - Google Patents

抗tim-3抗体を投与する方法 Download PDF

Info

Publication number
JP2022505923A
JP2022505923A JP2021523009A JP2021523009A JP2022505923A JP 2022505923 A JP2022505923 A JP 2022505923A JP 2021523009 A JP2021523009 A JP 2021523009A JP 2021523009 A JP2021523009 A JP 2021523009A JP 2022505923 A JP2022505923 A JP 2022505923A
Authority
JP
Japan
Prior art keywords
seq
tim
antibody
cdr
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021523009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505923A5 (cg-RX-API-DMAC7.html
Inventor
ルイージ,メアリー
ザイナゲットディノフ,リナット
チャン,ドン
ザオ,シンヤン
アン,チー
ナネマン,デイビッド
スード,ヴァニタ,ディー.
イフラント,クリステル
Original Assignee
メルク パテント ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク パテント ゲーエムベーハー filed Critical メルク パテント ゲーエムベーハー
Publication of JP2022505923A publication Critical patent/JP2022505923A/ja
Publication of JP2022505923A5 publication Critical patent/JP2022505923A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021523009A 2018-11-01 2019-11-01 抗tim-3抗体を投与する方法 Pending JP2022505923A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862754378P 2018-11-01 2018-11-01
US62/754,378 2018-11-01
PCT/US2019/059556 WO2020093024A2 (en) 2018-11-01 2019-11-01 Methods of administering anti-tim-3 antibodies

Publications (2)

Publication Number Publication Date
JP2022505923A true JP2022505923A (ja) 2022-01-14
JP2022505923A5 JP2022505923A5 (cg-RX-API-DMAC7.html) 2022-11-08

Family

ID=69159932

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523009A Pending JP2022505923A (ja) 2018-11-01 2019-11-01 抗tim-3抗体を投与する方法

Country Status (8)

Country Link
US (1) US20220073616A1 (cg-RX-API-DMAC7.html)
EP (1) EP3873612A2 (cg-RX-API-DMAC7.html)
JP (1) JP2022505923A (cg-RX-API-DMAC7.html)
CN (1) CN113301961A (cg-RX-API-DMAC7.html)
AU (1) AU2019372436A1 (cg-RX-API-DMAC7.html)
CA (1) CA3117371A1 (cg-RX-API-DMAC7.html)
IL (1) IL282708A (cg-RX-API-DMAC7.html)
WO (1) WO2020093024A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
IL268995B2 (en) 2017-03-02 2024-02-01 Nat Res Council Canada TGF-B receptor ectodomain fusion compounds and their uses
CA3183673A1 (en) * 2020-06-26 2021-12-30 Robert Allen Oncolytic herpes simplex viruses (hsv) expressing immunomodulatory fusion proteins
JP2024514590A (ja) * 2021-04-13 2024-04-02 メディミューン,エルエルシー Pd-1及びtim-3を標的化する二重特異性抗体
CN117377692A (zh) 2021-04-23 2024-01-09 苏州逻晟生物医药有限公司 Tim-3-靶向抗体及其用途
WO2022271917A1 (en) * 2021-06-24 2022-12-29 Bristol-Myers Squibb Company Transforming growth factor-beta ligand traps for the treatment of disease
CN116688115B (zh) * 2022-03-18 2024-02-06 上海齐鲁制药研究中心有限公司 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US7919092B2 (en) * 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
WO2013006490A2 (en) * 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
HRP20210977T1 (hr) 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
DK3169706T3 (da) * 2014-07-11 2020-03-09 Genmab As Antistoffer, der binder axl
SG11201702401RA (en) * 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗pd-1抗體類和使用彼等之方法
US20180207273A1 (en) * 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN109414500B (zh) * 2016-06-13 2022-02-25 奥美药业有限公司 治疗和诊断用pd-l1特异性单克隆抗体
US10988465B2 (en) * 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
JOP20190013A1 (ar) * 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
MA50677A (fr) * 2016-11-01 2021-07-14 Anaptysbio Inc Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
TW201825513A (zh) * 2016-11-29 2018-07-16 美商提薩羅有限公司 針對t細胞免疫球蛋白及黏蛋白3(tim-3)之抗體
CN110050000B (zh) 2017-05-12 2022-07-26 苏州盛迪亚生物医药有限公司 含有TGF-β受体的融合蛋白及其医药用途

Also Published As

Publication number Publication date
US20220073616A1 (en) 2022-03-10
CA3117371A1 (en) 2020-05-07
WO2020093024A3 (en) 2020-06-04
AU2019372436A1 (en) 2021-05-20
WO2020093024A2 (en) 2020-05-07
EP3873612A2 (en) 2021-09-08
IL282708A (en) 2021-06-30
CN113301961A (zh) 2021-08-24

Similar Documents

Publication Publication Date Title
JP7844558B2 (ja) リンパ球における阻害経路の中和
KR102821932B1 (ko) 항-ccr8 항체 및 이의 용도
KR102089072B1 (ko) 항-인간 4-1bb 항체 및 그의 용도
KR102714165B1 (ko) 인간 cd137에 결합하는 작동자 항체 및 이의 용도
CN113929782B (zh) 对淋巴细胞中抑制途径的中和
ES2908916T3 (es) Anticuerpos anti-tim-3
CN110945026B (zh) 仅有重链的抗bcma抗体
US20220073616A1 (en) Methods of administering anti-tim-3 antibodies
JP2022505925A (ja) 抗tim-3抗体
KR20210031479A (ko) Cd137 및 ox40에 결합하는 항체 분자
KR20170068458A (ko) 항-nkg2a 항체를 사용한 치료 요법
CN114981301B (zh) Pd1和vegfr2双结合剂
KR20230116007A (ko) 항-cd30 항체-약물 접합체를 사용한 면역 반응 조절
KR20230050378A (ko) 항-cd73 항체를 사용하여 암을 치료하는 방법
KR20220151172A (ko) 항-gitr 항체 및 이의 용도
WO2023164872A1 (en) Anti-cd39 antibodies and use thereof
KR20210131312A (ko) 인간 cd137에 결합하는 항체의 제제 및 이의 용도
CN117203236A (zh) 包含4-1bb和ox40结合蛋白的组合物及其使用方法
HK40059550A (en) Methods of administering anti-tim-3 antibodies
HK40058527A (en) Anti-tim-3 antibodies
HK40124330A (en) Anti-cd39 antibodies and use thereof
HK40124330B (en) Anti-cd39 antibodies and use thereof
HK40113788A (en) Anti-cd39 antibodies and use thereof
WO2024165403A1 (en) Anti-cea antibodies
JP2025532758A (ja) 癌の治療における使用のためのbtn3a活性化抗体、bcl2阻害剤及び低メチル化剤の併用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240419